German startup Pieris hopes they could prove a cheaper alternative to antibodies. (Click here for company profile.) The structure of lipocalins was first elucidated during the early 1980s ...

The focus of the combined company is developing new treatment for rare genetic skin diseases. Palvella Therapeutics completed a reverse merger with Pieris Pharmaceutical of Boston to become a ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Pieris Pharmaceuticals ( (PIRS)) has shared an announcement. Pieris Pharmaceuticals announced the approval of ...